Abstracts

1104 – Impact of a Tailored Patient Support Mobile App on Viral Suppression and HIV Care Engagement

Background Disparities in HIV care persist and there is a need to evaluate novel and scalable approaches to improving care engagement and viral suppression in real-world settings. Methods Participants were enrolled from six Baltimore HIV clinics in an individual-level randomized controlled trial. Eligibility criteria included adults living with HIV who had a new HIV diagnosis,…

398 – A Tissue Microenvironment Analogous to Specific Tumor Microenvironments May Enable HIV Persistence

Background Although antiretroviral therapy(ART) has demonstrated remarkable success in HIV treatment, interruption or termination of ART results in rapid viral rebound. Viral rebound occurs due to cells in tissues containing replication-competent HIV that persist during ART and constitute the HIV reservoir. Previous studies in rhesus macaques(RM) comparing the eclipse phase foci of rebound 4-5 days…

417 – Low-Level HIV-1 Viremia on ART Is Stable Over 6 Months

Background Although antiretroviral therapy (ART) inhibits HIV-1 replication and suppresses plasma HIV-1 RNA to below the clinical assay limit of detection (20-40 copies(cp)/mL), low-level viremia (LLV) can still be detected by more sensitive, single-copy assays (SCAs). Screening for changes in LLV after curative interventions could provide a simple, high-throughput indicator of initial evidence of potential…

708 – Ex Vivo Antigen Stimulation Affects the Abundance of the T Cell–Monocyte Complex in PLWH

Background CD3⁺ CD14⁺ T cell–monocyte complexes are markers of immune activation implicated in chronic inflammation, viral persistence, and metabolic dysregulation. Their function in the development of insulin resistance among people living with HIV (PLWH) is not well understood. Methods We studied 62 PLWH from the CFAR Network of Integrated Clinical Systems (CNICS) cohort. Metabolic groups…

763 – Skin Color Changes With a 3-Month Clofazimine-Containing TB Regimen: Results From the Clo-Fast Trial

Background Shortening the duration of tuberculosis (TB) treatment is a WHO priority. The ACTG Clo-Fast trial compared a 3-month regimen of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine loading dose (3HPZEC), to the standard 6-month regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) in drug-susceptible TB (DS-TB). Skin hyperpigmentation is a major…

553 – Noncanonical Resistance Mutations in TLD-Treated Individuals With Unexplained Virologic Failure

Background Dolutegravir (DTG)-based first-line regimens (TLD) achieve high rates of viral suppression, with integrase (IN) resistance mutations rarely detected in treatment-naïve individuals. However, some patients experience virological failure (VF) despite good adherence and absence of IN mutations, suggesting alternative non-canonical resistance pathways such as mutations in HIV-1 envelope (Env) and gag nucleocapsid (Gag-NC). Methods We…

819 – Very Early Seroreversion Among Infants Exposed to HIV in the Context of Effective Maternal ART

Background Increasingly, women with HIV (WHIV) begin effective antiretroviral therapy (ART) prior to conception, resulting in long-term sustained viral suppression. This may lead to lower circulating anti-HIV antibody levels during pregnancy and subsequently reduced maternal HIV antibody transfer to the fetus in utero. The objective of this study was to determine time to seroreversion among…

838 – Basal Proviral Transcription and Immune Correlates in Well-Suppressed Youths With Perinatal HIV-1

Background Background In adults with HIV-1, persistent proviral transcription despite years of sustained virologic suppression (VS) reflects a pool of long-term transcriptionally competent proviruses that may be targets for ART-free remission and cure therapies. Whether transcriptionally active proviruses persist and affect the immune system in adolescents living with longstanding perinatal HIV-1 (AdWPH) is unknown. Methods…

843 – Safety and Pharmacokinetics of Combination VRC07-523LS, PGDM1400LS, and PGT.121.414.LS in Children

Background Broadly neutralizing monoclonal antibodies (bNAbs) suppress HIV RNA and may promote HIV remission. We evaluated safety and pharmacokinetics (PK) of intravenous VRC07-523LS, PGDM1400LS, and PGT.121.414.LS in children with HIV on suppressive antiretroviral treatment (ART). Methods Children eligible for the safety and PK phase of the Tatelo Plus / IMPAACT 2042 Study received ART from <7…